<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976741</url>
  </required_header>
  <id_info>
    <org_study_id>16443</org_study_id>
    <secondary_id>2013-002155-15</secondary_id>
    <nct_id>NCT01976741</nct_id>
  </id_info>
  <brief_title>Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)</brief_title>
  <official_title>An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  This was the first study where BAY1163877 was given to humans. Impact of the study was
           to evaluate if patients with advanced solid cancers show advanced clinical benefit under
           the treatment with the pan FGFR inhibitor. Patients (all comers) received the study drug
           treatment in a dose-escalation scheme (no placebo group) to determine the safety,
           tolerability and maximum tolerated dose (MTD) of BAY1163877. The relative
           bioavailability of liquid service formulation and tablets was determined.

        -  After the MTD was defined patients with solid tumors (all comers), lung cancer (lung
           adenocarcinoma &amp; squamous non-small cell lung cancer), head and neck cancer or bladder
           cancer was enrolled according to their FGFR expression profile (biomarker
           stratification).

        -  The study also assessed the pharmacokinetics, biomarker status, pharmacodynamic
           parameters and tumor response of BAY1163877.

        -  BAY1163877 was given twice daily as oral application. Treatment was stopped if the tumor
           continued to grow, if side effects, which the patient cannot tolerate, occurred or if
           the patient decided to exit treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2013</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Drug Limiting Toxicities (DLTs) During Cycle 1 is Below 20%</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The MTD was defined as maximum dose at which the incidence of Drug Limiting Toxicities (DLTs) during Cycle 1 is below 20%. DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug. BID=twice daily.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of DLTs During Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
    <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
    <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md (Cmax After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Cmax,md (Cmax after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax/Dmd (Cmax Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Cmax/Dmd (Cmax divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md (AUC(0-12) After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>AUC(0-12)md (AUC(0-12) after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)/Dmd (AUC(0-12) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>AUC(0-12)/Dmd (AUC(0-12) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)md (AUC(0-tlast) After Multiple Dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>AUC(0-tlast)md (AUC(0-tlast) after multiple dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)/Dmd (AUC(0-tlast) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>AUC(0-tlast)/Dmd (AUC(0-tlast) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(0-12) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 12 Hours Post Administration) of BAY1163877</measure>
    <time_frame>On Cycle1, Day 1</time_frame>
    <description>AE,ur(0-12) (amount of drug excreted via urine during the collection interval 0 - 12 hours post administration) of BAY1163877.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 24 Hours Post Administration) of BAY1163877</measure>
    <time_frame>On Cycle1, Day 1</time_frame>
    <description>AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0 - 24 hours post administration) of BAY1163877.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(12-24) (Amount of Drug Excreted Via Urine During the Collection Interval 12 - 24 Hours Post Administration) of BAY1163877</measure>
    <time_frame>On Cycle1, Day 1</time_frame>
    <description>AE,ur(12-24) (amount of drug excreted via urine during the collection interval 12 - 24 hours post administration) of BAY1163877.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate as Defined by RECIST Version 1.1 Reported as Number of Participants With Different Response Type</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response as defined by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1: complete response (CR: disappearance of all target lesions), partial response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as the reference the baseline sum of diameters), stable disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference, the smallest sum of diameters while in the trial), progressive disease (PD: at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS was defined as the time (days) from the date of the first dose of study drug to the date of the first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented. PFS for participants without tumor progression at the time of analysis was censored at their last date of tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TTP was defined as the time from start of study treatment until first observed disease progression (radiological or clinical). Progression is defined using RECIST v1.0, as at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR (for partial and complete response (PR/CR)) was defined as the time (days) from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). DOR was calculated for responders only, i.e. participants with complete or partial response. Therefore, the dose escalation group is not displayed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment (DOT)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Biomarker Status - Number of Participants With Any Significant Change in FGF23 (Fibroblast Growth Factor 23) From Baseline to End of Study</measure>
    <time_frame>From baseline up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacodynamic Parameters (PD) - Change of Heart Rate (HR) From Baseline to End of Study</measure>
    <time_frame>From baseline up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacodynamic Parameters (PD) - Change of Blood Pressure (BP) From Baseline to End of Study</measure>
    <time_frame>From baseline up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacodynamic Parameters (PD) - Change of QT Intervals From Baseline up to Cycle 1, Day 15</measure>
    <time_frame>From baseline up to Cycle 1, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Relative Bioavailability of the Tablet Formulation in Comparison to the Solution Formulation of BAY1163877</measure>
    <time_frame>On Cycle 1, Day -3 and Cycle 1, Day 1</time_frame>
    <description>In order to evaluate the relative bioavailability of the tablet formulation, tablet Cmax/D, AUC(0-tlast)/D, and AUC/D on Cycle 1, Day -3 was compared to solution Cmax/D, AUC(0-tlast)/D, AUC/D on Cycle 1, Day 1 for all analytes. The logarithms of the PK parameters was analyzed using analysis of variance (ANOVA) including subject and formulation effects. Based on these analyses, point estimates (LS-means) and exploratory 90% confidence intervals for the ratios (tablet/solution) of Cmax/D, AUC(0- tlast)/D, and AUC/D was calculated by re-transformation of the logarithmic data using the intra-individual standard deviation of the ANOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Time to Reach Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
    <description>Tmax (time to reach maximum drug concentration in plasma) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast (Time of Last Plasma Concentration Above LLOQ) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
    <description>Tlast (time of last plasma concentration above LLOQ) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 (Half-life Associated With the Terminal Slope) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
    <description>T1/2 (half-life associated with the terminal slope) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast,md (Time of Last Plasma Concentration Above LLOQ After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</measure>
    <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
    <description>Tlast,md (time of last plasma concentration above LLOQ after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 50 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 600 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib dose escalation - 800 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib Dose Expansion (All Comers)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.
(1600 mg/day) in 21-days cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib Dose Expansion (BC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib Dose Expansion (SCCHN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rogaratinib Dose Expansion (sqNSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rogaratinib (BAY1163877) oral solution</intervention_name>
    <description>Participants received Rogaratinib oral solution on a continuous schedule starting with single-dose administration on Cycle 1, Day 1, followed by a &quot;drug-free day&quot; (Cycle 1, Day 2). 50 mg or 100 mg Rogaratinib solution were given twice daily (b.i.d., in total 100 mg or 200 mg) from Cycle 1, Day 3 ongoing for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.</description>
    <arm_group_label>Rogaratinib dose escalation - 100 mg BID</arm_group_label>
    <arm_group_label>Rogaratinib dose escalation - 50 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rogaratinib (BAY1163877) oral tablet</intervention_name>
    <description>Participants received Rogaratinib oral tablet on a continuous schedule starting with single-dose administration on Cycle 1, Day 1, followed by a &quot;drug-free day&quot; (Cycle 1, Day 2). 200 mg, 400 mg, 600 mg or 800 mg Rogaratinib tablet were given b.i.d. (in total 400 mg, 800 mg, 1200mg or 1600 mg) from Cycle 1, Day 3 ongoing for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.</description>
    <arm_group_label>Rogaratinib dose escalation - 100 mg BID</arm_group_label>
    <arm_group_label>Rogaratinib dose escalation - 200 mg BID</arm_group_label>
    <arm_group_label>Rogaratinib dose escalation - 400 mg BID</arm_group_label>
    <arm_group_label>Rogaratinib dose escalation - 600 mg BID</arm_group_label>
    <arm_group_label>Rogaratinib dose escalation - 800 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rogaratinib (BAY1163877) 800 mg BID</intervention_name>
    <description>Participants received 800 mg (4*200 mg tablets) Rogaratinib b.i.d. (in total 1600 mg) from Cycle 1, Day 1 ongoing in 21-days Cycles.</description>
    <arm_group_label>Rogaratinib Dose Expansion (All Comers)</arm_group_label>
    <arm_group_label>Rogaratinib Dose Expansion (BC)</arm_group_label>
    <arm_group_label>Rogaratinib Dose Expansion (SCCHN)</arm_group_label>
    <arm_group_label>Rogaratinib Dose Expansion (sqNSCLC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For dose escalation: Participants with any type of solid tumor (all comer) were
             eligible for dose escalation and dose expansion at MTD in Part 1; Participants
             enrolled for dose expansion (MTD expansion cohort &quot;all comer&quot;) were stratified
             according to high fibroblast growth factor receptor (FGFR) expression levels / FGFR
             mutation using archival or fresh tumor biopsy material

          -  For expansion cohorts: Participants were eligible for Part 2 only if they have
             histological or cytological confirmed squamous non-small cell lung cancer (sqNSCLC),
             lung adenocarcinoma, head and neck cancer or bladder cancer (BC). All participants in
             Part 2 were stratified according to high FGFR expression levels FGFR mutation using
             archival or fresh tumor biopsy specimen. BC participants with low overall FGFR
             expression levels could be included if activating FGFR3 (FGFR tyrosine kinases 3)
             mutations were confirmed

          -  Participants must have measurable disease (Response evaluation criteria in solid
             tumors (RECIST 1.1))

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2

          -  Bone marrow, liver and renal functions as assessed by adequate laboratory methods to
             be conducted within 7 days prior to starting study Treatment

          -  Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m^2 according to the modified diet
             in renal disease (MDRD) abbreviated formula

        Exclusion Criteria:

          -  Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase
             inhibitors or FGFR-specific antibodies)

          -  Concomitant therapies that cannot be discontinued or switched to a different
             medication prior to study entry that are known to increase serum phosphate levels are
             not permitted within 4 weeks prior to start of study treatment)

          -  Anticancer chemotherapy or immunotherapy during the study or within 5-halflives prior
             to start of study treatment. Mitomycin C, nitrosoureas or monoclonal antibodies with
             anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6
             weeks before starting to receive study treatment or within 6 weeks of pre-treatment
             biopsy for biomarker (p-ERK1/2) studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weiden</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chur</city>
        <state>Graubünden</state>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.</citation>
    <PMID>31405822</PMID>
  </results_reference>
  <results_reference>
    <citation>Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.</citation>
    <PMID>30807645</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <results_first_submitted>March 8, 2020</results_first_submitted>
  <results_first_submitted_qc>April 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2020</results_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>refractory, locally advanced or metastatic solid tumor</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>squamous non-small cell lung cancer</keyword>
  <keyword>pan-FGFR inhibitor</keyword>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>head and neck cancer</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01976741/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01976741/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 29 centers in 7 countries, between 30 Dec 2013 (first subject first visit) and 27 Nov 2019 (last subject last visit).</recruitment_details>
      <pre_assignment_details>A total of 988 participants were screened, of whom 168 participants were assigned into the study and received at least one dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rogaratinib Dose Escalation – 50 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P2">
          <title>Rogaratinib Dose Escalation – 100 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P3">
          <title>Rogaratinib Dose Escalation – 200 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P4">
          <title>Rogaratinib Dose Escalation – 400 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P5">
          <title>Rogaratinib Dose Escalation – 600 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P6">
          <title>Rogaratinib Dose Escalation – 800 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="P7">
          <title>Rogaratinib Dose Expansion (All Comers)</title>
          <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="P8">
          <title>Rogaratinib Dose Expansion (BC)</title>
          <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="P9">
          <title>Rogaratinib Dose Expansion (SCCHN)</title>
          <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="P10">
          <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
          <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="74"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="62"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rogaratinib Dose Escalation – 50 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B2">
          <title>Rogaratinib Dose Escalation – 100 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B3">
          <title>Rogaratinib Dose Escalation – 200 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B4">
          <title>Rogaratinib Dose Escalation – 400 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B5">
          <title>Rogaratinib Dose Escalation – 600 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B6">
          <title>Rogaratinib Dose Escalation – 800 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="B7">
          <title>Rogaratinib Dose Expansion (All Comers)</title>
          <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="B8">
          <title>Rogaratinib Dose Expansion (BC)</title>
          <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="B9">
          <title>Rogaratinib Dose Expansion (SCCHN)</title>
          <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="B10">
          <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
          <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="74"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="40"/>
            <count group_id="B11" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="20.4"/>
                    <measurement group_id="B2" value="58.5" spread="12.4"/>
                    <measurement group_id="B3" value="55.8" spread="15.3"/>
                    <measurement group_id="B4" value="56.3" spread="9.8"/>
                    <measurement group_id="B5" value="56.8" spread="12.9"/>
                    <measurement group_id="B6" value="64.3" spread="8.4"/>
                    <measurement group_id="B7" value="63.0" spread="7.8"/>
                    <measurement group_id="B8" value="66.4" spread="8.6"/>
                    <measurement group_id="B9" value="63.4" spread="11.1"/>
                    <measurement group_id="B10" value="62.6" spread="6.6"/>
                    <measurement group_id="B11" value="63.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="32"/>
                    <measurement group_id="B11" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="61"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="34"/>
                    <measurement group_id="B11" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="50"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance status</title>
          <description>ECOG score: 0=fully active; 1=restricted active; 2=ambulatory and capable of all self-care.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ECOG=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="14"/>
                    <measurement group_id="B11" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="49"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="22"/>
                    <measurement group_id="B11" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Drug Limiting Toxicities (DLTs) During Cycle 1 is Below 20%</title>
        <description>The MTD was defined as maximum dose at which the incidence of Drug Limiting Toxicities (DLTs) during Cycle 1 is below 20%. DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug. BID=twice daily.</description>
        <time_frame>Up to 21 days</time_frame>
        <population>All participants in the dose escalation phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Drug Limiting Toxicities (DLTs) During Cycle 1 is Below 20%</title>
          <description>The MTD was defined as maximum dose at which the incidence of Drug Limiting Toxicities (DLTs) during Cycle 1 is below 20%. DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug. BID=twice daily.</description>
          <population>All participants in the dose escalation phase.</population>
          <units>mg BID</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of DLTs During Cycle 1</title>
        <description>DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug.</description>
        <time_frame>Up to 21 days</time_frame>
        <population>All participants in the dose escalation phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of DLTs During Cycle 1</title>
          <description>DLT was defined as any of the pre-defined adverse events occurring during Cycle 1 of a dose level and regarded by the investigators and/or sponsor to be related to the investigational drug.</description>
          <population>All participants in the dose escalation phase.</population>
          <units>DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid pharmacokinetic (PK) data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid pharmacokinetic (PK) data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>µg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2760" spread="56.5"/>
                    <measurement group_id="O2" value="11300" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Maximum drug concentration in plasma (Cmax) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3640" spread="16.8"/>
                    <measurement group_id="O2" value="4360" spread="36.4"/>
                    <measurement group_id="O3" value="5630" spread="46.2"/>
                    <measurement group_id="O4" value="9480" spread="16.1"/>
                    <measurement group_id="O5" value="9060" spread="32.3"/>
                    <measurement group_id="O6" value="10200" spread="17.3"/>
                    <measurement group_id="O7" value="11000" spread="34.3"/>
                    <measurement group_id="O8" value="11000" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15600" spread="72.0"/>
                    <measurement group_id="O2" value="71000" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12) (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to 12 hours (AUC(0-12)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12100" spread="16.3"/>
                    <measurement group_id="O2" value="15300" spread="41.4"/>
                    <measurement group_id="O3" value="33200" spread="33.1"/>
                    <measurement group_id="O4" value="44000" spread="68.9"/>
                    <measurement group_id="O5" value="54300" spread="31.3"/>
                    <measurement group_id="O6" value="55700" spread="43.5"/>
                    <measurement group_id="O7" value="63900" spread="45.0"/>
                    <measurement group_id="O8" value="74200" spread="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20000" spread="87.3"/>
                    <measurement group_id="O2" value="99300" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast) (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ [Lower Limit of Quantification]) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ [lower limit of quantification] (AUC(0-tlast)) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14200" spread="24.4"/>
                    <measurement group_id="O2" value="20100" spread="57.7"/>
                    <measurement group_id="O3" value="43800" spread="36.3"/>
                    <measurement group_id="O4" value="62000" spread="114"/>
                    <measurement group_id="O5" value="78000" spread="38.5"/>
                    <measurement group_id="O6" value="86600" spread="41.2"/>
                    <measurement group_id="O7" value="103000" spread="53.5"/>
                    <measurement group_id="O8" value="121000" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20200" spread="87.1"/>
                    <measurement group_id="O2" value="102000" spread="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Area Under the Plasma Concentration vs Time Curve From Zero to Infinity) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Area under the plasma concentration vs time curve from zero to infinity (AUC) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14300" spread="24.5"/>
                    <measurement group_id="O2" value="20700" spread="58.1"/>
                    <measurement group_id="O3" value="44300" spread="37.1"/>
                    <measurement group_id="O4" value="64000" spread="118"/>
                    <measurement group_id="O5" value="79800" spread="39.5"/>
                    <measurement group_id="O6" value="95400" spread="48.7"/>
                    <measurement group_id="O7" value="109000" spread="58.4"/>
                    <measurement group_id="O8" value="133000" spread="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0276" spread="56.5"/>
                    <measurement group_id="O2" value="0.0141" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/D (Maximum Drug Concentration in Plasma Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Maximum drug concentration in plasma divided by dose (Cmax/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0728" spread="16.8"/>
                    <measurement group_id="O2" value="0.0436" spread="36.4"/>
                    <measurement group_id="O3" value="0.0282" spread="46.2"/>
                    <measurement group_id="O4" value="0.0237" spread="16.1"/>
                    <measurement group_id="O5" value="0.0151" spread="32.3"/>
                    <measurement group_id="O6" value="0.0127" spread="17.3"/>
                    <measurement group_id="O7" value="0.0138" spread="34.3"/>
                    <measurement group_id="O8" value="0.0137" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.9361</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean</param_type>
            <param_value>73.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.50</ci_lower_limit>
            <ci_upper_limit>88.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="72.0"/>
                    <measurement group_id="O2" value="0.0888" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to 12 Hours Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to 12 hours divided by dose (AUC(0-12)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="16.3"/>
                    <measurement group_id="O2" value="0.153" spread="41.4"/>
                    <measurement group_id="O3" value="0.166" spread="33.1"/>
                    <measurement group_id="O4" value="0.110" spread="68.9"/>
                    <measurement group_id="O5" value="0.0906" spread="31.3"/>
                    <measurement group_id="O6" value="0.0696" spread="43.5"/>
                    <measurement group_id="O7" value="0.0798" spread="45.0"/>
                    <measurement group_id="O8" value="0.0927" spread="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" spread="87.3"/>
                    <measurement group_id="O2" value="0.124" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast)/D (Area Under the Plasma Concentration vs Time Curve From Time Zero to the Last Data Point &gt; LLOQ Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>Area under the plasma concentration vs time curve from time zero to the last data point &gt; LLOQ divided by dose (AUC(0-tlast)/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.283" spread="24.4"/>
                    <measurement group_id="O2" value="0.201" spread="57.7"/>
                    <measurement group_id="O3" value="0.219" spread="36.3"/>
                    <measurement group_id="O4" value="0.155" spread="114"/>
                    <measurement group_id="O5" value="0.130" spread="38.5"/>
                    <measurement group_id="O6" value="0.108" spread="41.2"/>
                    <measurement group_id="O7" value="0.129" spread="53.5"/>
                    <measurement group_id="O8" value="0.152" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.1828</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.5377</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean</param_type>
            <param_value>6.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.04</ci_lower_limit>
            <ci_upper_limit>8.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
        <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day -2) and 48 hour(s) post-dose (Day -1)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3</title>
          <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day -3. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="87.1"/>
                    <measurement group_id="O2" value="0.127" spread="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
        <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 (Day 1) and 48 hour(s) post-dose (Day 2)</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC/D (AUC Divided by Dose) of BAY1163877 After Single Dose Administration on Cycle 1, Day 1</title>
          <description>AUC divided by dose (AUC/D) of BAY1163877 after single dose administration on Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.286" spread="24.5"/>
                    <measurement group_id="O2" value="0.207" spread="58.1"/>
                    <measurement group_id="O3" value="0.221" spread="37.1"/>
                    <measurement group_id="O4" value="0.160" spread="118"/>
                    <measurement group_id="O5" value="0.133" spread="39.5"/>
                    <measurement group_id="O6" value="0.119" spread="48.7"/>
                    <measurement group_id="O7" value="0.137" spread="58.4"/>
                    <measurement group_id="O8" value="0.166" spread="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.3264</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.4888</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean</param_type>
            <param_value>6.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.52</ci_lower_limit>
            <ci_upper_limit>8.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax,md (Cmax After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>Cmax,md (Cmax after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,md (Cmax After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>Cmax,md (Cmax after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3940" spread="38.5"/>
                    <measurement group_id="O2" value="4870" spread="35.2"/>
                    <measurement group_id="O3" value="8320" spread="68.9"/>
                    <measurement group_id="O4" value="9490" spread="63.1"/>
                    <measurement group_id="O5" value="10500" spread="32.6"/>
                    <measurement group_id="O6" value="12400" spread="33.8"/>
                    <measurement group_id="O7" value="12600" spread="34.6"/>
                    <measurement group_id="O8" value="11000" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax/Dmd (Cmax Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>Cmax/Dmd (Cmax divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/Dmd (Cmax Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>Cmax/Dmd (Cmax divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0789" spread="38.5"/>
                    <measurement group_id="O2" value="0.0487" spread="35.2"/>
                    <measurement group_id="O3" value="0.0416" spread="68.9"/>
                    <measurement group_id="O4" value="0.0237" spread="63.1"/>
                    <measurement group_id="O5" value="0.0174" spread="32.6"/>
                    <measurement group_id="O6" value="0.0155" spread="33.8"/>
                    <measurement group_id="O7" value="0.0158" spread="34.6"/>
                    <measurement group_id="O8" value="0.0138" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.0005</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.8224</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean</param_type>
            <param_value>72.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.68</ci_lower_limit>
            <ci_upper_limit>90.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12)md (AUC(0-12) After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>AUC(0-12)md (AUC(0-12) after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12)md (AUC(0-12) After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>AUC(0-12)md (AUC(0-12) after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="69"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13300" spread="75.4"/>
                    <measurement group_id="O2" value="21500" spread="98.5"/>
                    <measurement group_id="O3" value="41700" spread="27.9"/>
                    <measurement group_id="O4" value="61100" spread="66.2"/>
                    <measurement group_id="O5" value="73500" spread="33.4"/>
                    <measurement group_id="O6" value="90900" spread="28.8"/>
                    <measurement group_id="O7" value="85300" spread="42.8"/>
                    <measurement group_id="O8" value="87100" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12)/Dmd (AUC(0-12) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>AUC(0-12)/Dmd (AUC(0-12) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12)/Dmd (AUC(0-12) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>AUC(0-12)/Dmd (AUC(0-12) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="69"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" spread="75.4"/>
                    <measurement group_id="O2" value="0.215" spread="98.5"/>
                    <measurement group_id="O3" value="0.209" spread="27.9"/>
                    <measurement group_id="O4" value="0.153" spread="66.2"/>
                    <measurement group_id="O5" value="0.123" spread="33.4"/>
                    <measurement group_id="O6" value="0.114" spread="28.8"/>
                    <measurement group_id="O7" value="0.107" spread="42.8"/>
                    <measurement group_id="O8" value="0.109" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast)md (AUC(0-tlast) After Multiple Dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>AUC(0-tlast)md (AUC(0-tlast) after multiple dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast)md (AUC(0-tlast) After Multiple Dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>AUC(0-tlast)md (AUC(0-tlast) after multiple dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>µg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12500" spread="78.5"/>
                    <measurement group_id="O2" value="21500" spread="99.8"/>
                    <measurement group_id="O3" value="39200" spread="19.1"/>
                    <measurement group_id="O4" value="60200" spread="65.8"/>
                    <measurement group_id="O5" value="72500" spread="33.3"/>
                    <measurement group_id="O6" value="89000" spread="30.9"/>
                    <measurement group_id="O7" value="81500" spread="43.4"/>
                    <measurement group_id="O8" value="84100" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-tlast)/Dmd (AUC(0-tlast) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>AUC(0-tlast)/Dmd (AUC(0-tlast) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlast)/Dmd (AUC(0-tlast) Divided by Dose After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>AUC(0-tlast)/Dmd (AUC(0-tlast) divided by dose after multiple-dose administration) of BAY1163877. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" spread="78.5"/>
                    <measurement group_id="O2" value="0.215" spread="99.8"/>
                    <measurement group_id="O3" value="0.196" spread="19.1"/>
                    <measurement group_id="O4" value="0.151" spread="65.8"/>
                    <measurement group_id="O5" value="0.121" spread="33.3"/>
                    <measurement group_id="O6" value="0.111" spread="30.9"/>
                    <measurement group_id="O7" value="0.102" spread="43.4"/>
                    <measurement group_id="O8" value="0.105" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.2631</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>dose proportionality</non_inferiority_desc>
            <p_value>0.9018</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean</param_type>
            <param_value>9.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.30</ci_lower_limit>
            <ci_upper_limit>12.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AE,ur(0-12) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 12 Hours Post Administration) of BAY1163877</title>
        <description>AE,ur(0-12) (amount of drug excreted via urine during the collection interval 0 - 12 hours post administration) of BAY1163877.</description>
        <time_frame>On Cycle1, Day 1</time_frame>
        <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AE,ur(0-12) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 12 Hours Post Administration) of BAY1163877</title>
          <description>AE,ur(0-12) (amount of drug excreted via urine during the collection interval 0 - 12 hours post administration) of BAY1163877.</description>
          <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5348" spread="1.3965"/>
                    <measurement group_id="O2" value="1.0090" spread="0.3555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 24 Hours Post Administration) of BAY1163877</title>
        <description>AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0 - 24 hours post administration) of BAY1163877.</description>
        <time_frame>On Cycle1, Day 1</time_frame>
        <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0 - 24 Hours Post Administration) of BAY1163877</title>
          <description>AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0 - 24 hours post administration) of BAY1163877.</description>
          <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7527" spread="1.4390"/>
                    <measurement group_id="O2" value="0.8799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AE,ur(12-24) (Amount of Drug Excreted Via Urine During the Collection Interval 12 - 24 Hours Post Administration) of BAY1163877</title>
        <description>AE,ur(12-24) (amount of drug excreted via urine during the collection interval 12 - 24 hours post administration) of BAY1163877.</description>
        <time_frame>On Cycle1, Day 1</time_frame>
        <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>AE,ur(12-24) (Amount of Drug Excreted Via Urine During the Collection Interval 12 - 24 Hours Post Administration) of BAY1163877</title>
          <description>AE,ur(12-24) (amount of drug excreted via urine during the collection interval 12 - 24 hours post administration) of BAY1163877.</description>
          <population>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics, as there was no significant difference of PK between tumor groups observed.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2179" spread="0.1290"/>
                    <measurement group_id="O2" value="0.1223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate as Defined by RECIST Version 1.1 Reported as Number of Participants With Different Response Type</title>
        <description>Response as defined by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1: complete response (CR: disappearance of all target lesions), partial response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as the reference the baseline sum of diameters), stable disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference, the smallest sum of diameters while in the trial), progressive disease (PD: at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study).</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate as Defined by RECIST Version 1.1 Reported as Number of Participants With Different Response Type</title>
          <description>Response as defined by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1: complete response (CR: disappearance of all target lesions), partial response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as the reference the baseline sum of diameters), stable disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference, the smallest sum of diameters while in the trial), progressive disease (PD: at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study).</description>
          <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time (days) from the date of the first dose of study drug to the date of the first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented. PFS for participants without tumor progression at the time of analysis was censored at their last date of tumor evaluation.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time (days) from the date of the first dose of study drug to the date of the first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented. PFS for participants without tumor progression at the time of analysis was censored at their last date of tumor evaluation.</description>
          <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="41" upper_limit="88"/>
                    <measurement group_id="O2" value="47" lower_limit="38" upper_limit="231"/>
                    <measurement group_id="O3" value="105" lower_limit="80" upper_limit="109"/>
                    <measurement group_id="O4" value="44" lower_limit="24" upper_limit="144"/>
                    <measurement group_id="O5" value="84" lower_limit="50" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>TTP was defined as the time from start of study treatment until first observed disease progression (radiological or clinical). Progression is defined using RECIST v1.0, as at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>TTP was defined as the time from start of study treatment until first observed disease progression (radiological or clinical). Progression is defined using RECIST v1.0, as at least a 20% increase in the sum of diameters of the target lesions, taking as a references the smallest sum on study.</description>
          <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="41" upper_limit="76"/>
                    <measurement group_id="O2" value="47" lower_limit="38" upper_limit="231"/>
                    <measurement group_id="O3" value="105" lower_limit="80" upper_limit="109"/>
                    <measurement group_id="O4" value="68" lower_limit="35" upper_limit="295"/>
                    <measurement group_id="O5" value="85" lower_limit="50" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR (for partial and complete response (PR/CR)) was defined as the time (days) from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). DOR was calculated for responders only, i.e. participants with complete or partial response. Therefore, the dose escalation group is not displayed.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Participants with a documented objective response of PR or CR.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>DOR (for partial and complete response (PR/CR)) was defined as the time (days) from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). DOR was calculated for responders only, i.e. participants with complete or partial response. Therefore, the dose escalation group is not displayed.</description>
          <population>Participants with a documented objective response of PR or CR.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522" lower_limit="NA" upper_limit="NA">Not Calculated</measurement>
                    <measurement group_id="O2" value="126" lower_limit="63" upper_limit="464"/>
                    <measurement group_id="O3" value="105" lower_limit="NA" upper_limit="NA">Not Calculated</measurement>
                    <measurement group_id="O4" value="225" lower_limit="65" upper_limit="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment (DOT)</title>
        <time_frame>Up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment (DOT)</title>
          <population>Participants received at least one dose of Rogaratinib and have post-baseline efficacy data available. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="39" upper_limit="80"/>
                    <measurement group_id="O2" value="82" lower_limit="43" upper_limit="126"/>
                    <measurement group_id="O3" value="106" lower_limit="86" upper_limit="119"/>
                    <measurement group_id="O4" value="49" lower_limit="12" upper_limit="147"/>
                    <measurement group_id="O5" value="84" lower_limit="51" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Biomarker Status - Number of Participants With Any Significant Change in FGF23 (Fibroblast Growth Factor 23) From Baseline to End of Study</title>
        <time_frame>From baseline up to 2 years</time_frame>
        <population>The study team grouped the patients as described in the SAP in order to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Biomarker Status - Number of Participants With Any Significant Change in FGF23 (Fibroblast Growth Factor 23) From Baseline to End of Study</title>
          <population>The study team grouped the patients as described in the SAP in order to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of Heart Rate (HR) From Baseline to End of Study</title>
        <time_frame>From baseline up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have valid data for this outcome measure. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of Heart Rate (HR) From Baseline to End of Study</title>
          <population>Participants received at least one dose of Rogaratinib and have valid data for this outcome measure. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.22" spread="12.47"/>
                    <measurement group_id="O2" value="6.41" spread="15.60"/>
                    <measurement group_id="O3" value="6.40" spread="14.40"/>
                    <measurement group_id="O4" value="1.42" spread="11.65"/>
                    <measurement group_id="O5" value="6.27" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of Blood Pressure (BP) From Baseline to End of Study</title>
        <time_frame>From baseline up to 2 years</time_frame>
        <population>Participants received at least one dose of Rogaratinib and have valid data for this outcome measure. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of Blood Pressure (BP) From Baseline to End of Study</title>
          <population>Participants received at least one dose of Rogaratinib and have valid data for this outcome measure. Participants were grouped as described in the SAP to allow a comparison of all dose escalation patients (all dose levels pooled together), dose expansion patients (four groups) and total number of patients (overview summaries) in the same table.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="16.44"/>
                    <measurement group_id="O2" value="-4.65" spread="16.73"/>
                    <measurement group_id="O3" value="-2.56" spread="19.45"/>
                    <measurement group_id="O4" value="-5.00" spread="12.37"/>
                    <measurement group_id="O5" value="-1.83" spread="18.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="13.50"/>
                    <measurement group_id="O2" value="-4.76" spread="6.99"/>
                    <measurement group_id="O3" value="-0.63" spread="12.08"/>
                    <measurement group_id="O4" value="-0.58" spread="9.23"/>
                    <measurement group_id="O5" value="0.41" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of QT Intervals From Baseline up to Cycle 1, Day 15</title>
        <time_frame>From baseline up to Cycle 1, Day 15</time_frame>
        <population>Safety Analysis Set (SAF): All participants who received at least one dose of the study medication, and valid data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Total Dose Escalation</title>
            <description>Participants with any type of solid tumor received escalating doses of BAY1163877 oral solution or tablet.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Expansion (All Comers)</title>
            <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Expansion (BC)</title>
            <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Expansion (SCCHN)</title>
            <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
            <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet BID (1600 mg/day) in 21-days cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacodynamic Parameters (PD) - Change of QT Intervals From Baseline up to Cycle 1, Day 15</title>
          <population>Safety Analysis Set (SAF): All participants who received at least one dose of the study medication, and valid data for this outcome measure.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="23.11"/>
                    <measurement group_id="O2" value="12.86" spread="24.16"/>
                    <measurement group_id="O3" value="7.82" spread="29.39"/>
                    <measurement group_id="O4" value="2.89" spread="16.47"/>
                    <measurement group_id="O5" value="6.41" spread="21.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Relative Bioavailability of the Tablet Formulation in Comparison to the Solution Formulation of BAY1163877</title>
        <description>In order to evaluate the relative bioavailability of the tablet formulation, tablet Cmax/D, AUC(0-tlast)/D, and AUC/D on Cycle 1, Day -3 was compared to solution Cmax/D, AUC(0-tlast)/D, AUC/D on Cycle 1, Day 1 for all analytes. The logarithms of the PK parameters was analyzed using analysis of variance (ANOVA) including subject and formulation effects. Based on these analyses, point estimates (LS-means) and exploratory 90% confidence intervals for the ratios (tablet/solution) of Cmax/D, AUC(0- tlast)/D, and AUC/D was calculated by re-transformation of the logarithmic data using the intra-individual standard deviation of the ANOVA.</description>
        <time_frame>On Cycle 1, Day -3 and Cycle 1, Day 1</time_frame>
        <population>Participants received both tablet and solution formulation.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Relative Bioavailability of the Tablet Formulation in Comparison to the Solution Formulation of BAY1163877</title>
          <description>In order to evaluate the relative bioavailability of the tablet formulation, tablet Cmax/D, AUC(0-tlast)/D, and AUC/D on Cycle 1, Day -3 was compared to solution Cmax/D, AUC(0-tlast)/D, AUC/D on Cycle 1, Day 1 for all analytes. The logarithms of the PK parameters was analyzed using analysis of variance (ANOVA) including subject and formulation effects. Based on these analyses, point estimates (LS-means) and exploratory 90% confidence intervals for the ratios (tablet/solution) of Cmax/D, AUC(0- tlast)/D, and AUC/D was calculated by re-transformation of the logarithmic data using the intra-individual standard deviation of the ANOVA.</description>
          <population>Participants received both tablet and solution formulation.</population>
          <units>ratio</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-tlast)/D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9945" lower_limit="0.7698" upper_limit="1.2847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC/D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9776" lower_limit="0.7609" upper_limit="1.2561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax/D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6335" lower_limit="0.4343" upper_limit="0.9240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (Time to Reach Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
        <description>Tmax (time to reach maximum drug concentration in plasma) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time to Reach Maximum Drug Concentration in Plasma) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
          <description>Tmax (time to reach maximum drug concentration in plasma) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="51"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O2" value="2.02" lower_limit="0.983" upper_limit="3.03"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O8" value="2.99" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="51"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.633" lower_limit="0.550" upper_limit="0.983"/>
                    <measurement group_id="O2" value="0.783" lower_limit="0.533" upper_limit="0.983"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.617" upper_limit="3.25"/>
                    <measurement group_id="O4" value="1.02" lower_limit="1.00" upper_limit="1.08"/>
                    <measurement group_id="O5" value="1.54" lower_limit="1.08" upper_limit="2.07"/>
                    <measurement group_id="O6" value="2.53" lower_limit="0.517" upper_limit="4.05"/>
                    <measurement group_id="O7" value="2.00" lower_limit="0.483" upper_limit="4.05"/>
                    <measurement group_id="O8" value="2.00" lower_limit="0.517" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast (Time of Last Plasma Concentration Above LLOQ) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
        <description>Tlast (time of last plasma concentration above LLOQ) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast (Time of Last Plasma Concentration Above LLOQ) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
          <description>Tlast (time of last plasma concentration above LLOQ) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Median and full range were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="51"/>
                <count group_id="O8" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day -3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="51"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O2" value="48.1" lower_limit="47.9" upper_limit="48.4"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">No data at the time point</measurement>
                    <measurement group_id="O8" value="48.0" lower_limit="46.6" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="51"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="46.4" upper_limit="47.8"/>
                    <measurement group_id="O2" value="47.9" lower_limit="23.9" upper_limit="48.3"/>
                    <measurement group_id="O3" value="47.9" lower_limit="6.0" upper_limit="48.6"/>
                    <measurement group_id="O4" value="46.9" lower_limit="24.1" upper_limit="48.0"/>
                    <measurement group_id="O5" value="48.0" lower_limit="47.7" upper_limit="48.1"/>
                    <measurement group_id="O6" value="47.9" lower_limit="47.8" upper_limit="49.5"/>
                    <measurement group_id="O7" value="47.9" lower_limit="11.6" upper_limit="49.5"/>
                    <measurement group_id="O8" value="47.6" lower_limit="8.0" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2 (Half-life Associated With the Terminal Slope) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
        <description>T1/2 (half-life associated with the terminal slope) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
        <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hour(s) post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (Half-life Associated With the Terminal Slope) of BAY1163877 After Single Dose Administration on Cycle 1, Day -3 and Cycle 1, Day 1</title>
          <description>T1/2 (half-life associated with the terminal slope) of BAY1163877 after single dose administration on Cycle 1, Day -3 and Cycle 1, Day 1. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day -3 and on Cycle 1, Day 1. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day -3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O2" value="8.15" spread="22.3"/>
                    <measurement group_id="O3" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">No data at the time point</measurement>
                    <measurement group_id="O8" value="8.22" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="24.9"/>
                    <measurement group_id="O2" value="8.93" spread="40.2"/>
                    <measurement group_id="O3" value="7.51" spread="19.2"/>
                    <measurement group_id="O4" value="7.93" spread="54.2"/>
                    <measurement group_id="O5" value="8.51" spread="29.4"/>
                    <measurement group_id="O6" value="9.29" spread="9.86"/>
                    <measurement group_id="O7" value="11.7" spread="44.3"/>
                    <measurement group_id="O8" value="12.5" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>Tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>Tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.50" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.50" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.12" lower_limit="1.05" upper_limit="4.02"/>
                    <measurement group_id="O4" value="2.08" lower_limit="0.50" upper_limit="2.17"/>
                    <measurement group_id="O5" value="2.10" lower_limit="2.00" upper_limit="3.08"/>
                    <measurement group_id="O6" value="2.56" lower_limit="1.05" upper_limit="5.53"/>
                    <measurement group_id="O7" value="2.00" lower_limit="0.00" upper_limit="5.53"/>
                    <measurement group_id="O8" value="3.17" lower_limit="1.00" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlast,md (Time of Last Plasma Concentration Above LLOQ After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
        <description>Tlast,md (time of last plasma concentration above LLOQ after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
        <time_frame>pre-dose (before morning dose), and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose</time_frame>
        <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rogaratinib Dose Escalation – 50 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O2">
            <title>Rogaratinib Dose Escalation – 100 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O3">
            <title>Rogaratinib Dose Escalation – 200 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O4">
            <title>Rogaratinib Dose Escalation – 400 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O5">
            <title>Rogaratinib Dose Escalation – 600 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O6">
            <title>Rogaratinib Dose Escalation – 800 mg BID</title>
            <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
          </group>
          <group group_id="O7">
            <title>Rogaratinib – Pooled 800 mg BID</title>
            <description>All participants from the 800 mg BID escalation as well as the 800 mg BID expansion cohorts were combined into a pooled 800 mg BID group for PK statistics. They received 800 mg Rogaratinib tablet BID (in total 1600 mg/day) in 21-days cycles.</description>
          </group>
          <group group_id="O8">
            <title>Rogaratinib Expansion Food Effect</title>
            <description>Some of the participants in the expansion cohorts were used for food effect assessment. They received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day -3 immediately (within 5 min) after consumption of a high-fat, high-calorie breakfast, and a second single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1 after an overnight fast of at least 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Tlast,md (Time of Last Plasma Concentration Above LLOQ After Multiple-dose Administration) of BAY1163877 on Cycle 1, Day 15</title>
          <description>Tlast,md (time of last plasma concentration above LLOQ after multiple-dose administration) of BAY1163877. Median and full range were reported.</description>
          <population>All participants with valid PK data on Cycle 1, Day 15. Some of the participants from the expansion cohorts were included in Rogaratinib expansion food effect, and participants received 800 mg BID in either escalation or expansion phase were combined as there was no significant difference of PK between tumor groups observed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" lower_limit="6.08" upper_limit="11.8"/>
                    <measurement group_id="O2" value="11.7" lower_limit="11.6" upper_limit="12.3"/>
                    <measurement group_id="O3" value="11.6" lower_limit="8.00" upper_limit="12.6"/>
                    <measurement group_id="O4" value="11.7" lower_limit="11.5" upper_limit="11.7"/>
                    <measurement group_id="O5" value="11.6" lower_limit="11.5" upper_limit="11.8"/>
                    <measurement group_id="O6" value="11.7" lower_limit="11.1" upper_limit="12.0"/>
                    <measurement group_id="O7" value="11.7" lower_limit="6.00" upper_limit="12.4"/>
                    <measurement group_id="O8" value="11.7" lower_limit="8.62" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first study drug administration up to 30 days after the end of treatment with study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rogaratinib Dose Escalation – 50 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E2">
          <title>Rogaratinib Dose Escalation – 100 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E3">
          <title>Rogaratinib Dose Escalation – 200 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E4">
          <title>Rogaratinib Dose Escalation – 400 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E5">
          <title>Rogaratinib Dose Escalation – 600 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E6">
          <title>Rogaratinib Dose Escalation – 800 mg BID</title>
          <description>Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.</description>
        </group>
        <group group_id="E7">
          <title>Rogaratinib Dose Expansion (All Comers)</title>
          <description>Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="E8">
          <title>Rogaratinib Dose Expansion (BC)</title>
          <description>Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="E9">
          <title>Rogaratinib Dose Expansion (SCCHN)</title>
          <description>Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
        </group>
        <group group_id="E10">
          <title>Rogaratinib Dose Expansion (sqNSCLC)</title>
          <description>Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="43" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="24" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="8" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dural arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="8" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Laryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nephrostomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="73" subjects_at_risk="74"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="11" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" events="29" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E9" events="6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" events="19" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="13" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Growth of eyelashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pingueculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="14" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="15" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E8" events="41" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" events="10" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="20" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E8" events="106" subjects_affected="48" subjects_at_risk="74"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E10" events="42" subjects_affected="23" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="42" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="13" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" events="11" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E8" events="30" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E10" events="19" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="18" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="13" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="17" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="35" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="9" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="12" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E8" events="53" subjects_affected="27" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="22" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" events="11" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="8" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="9" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="32" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" events="20" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="11" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="20" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="14" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" events="19" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="13" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="9" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="24" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="11" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="16" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="13" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="40" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E9" events="5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="25" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="9" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" events="7" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" events="58" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E8" events="88" subjects_affected="31" subjects_at_risk="74"/>
                <counts group_id="E9" events="11" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" events="85" subjects_affected="31" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="12" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="13" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" events="10" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="18" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="11" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="25" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="12" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="10" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="12" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E8" events="50" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E9" events="9" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E10" events="17" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="9" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" events="30" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="16" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="9" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chest wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="20" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="8" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="13" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="19" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="9" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="19" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="10" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Laryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="5" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" events="23" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="10" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="22" subjects_affected="17" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="13" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nail hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="22" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="16" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="9" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoid operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer</organization>
      <phone>(+)1-888-84 22937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

